Loading
2 standard-of-care settings across 2 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Making the diagnosis, and why it is missed | The cells look like plasma cells and the surface markers agree with that appearance, so the differential diagnosis includes myeloma with plasmablastic features rather than other lymphomas. What separates them is the clinical picture: a rapidly growing mass, usually in the mouth or jaw or the gut, in a younger person, often with HIV, with Epstein-Barr virus in the cells and a very high proliferation index. HIV testing belongs in every work-up. | WHO Classification of Haematolymphoid Tumours, 5th edition (2022), with the International Consensus Classification (2022) where they differ | 95 |
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Treatment | Combination chemotherapy more intensive than standard immunochemotherapy, because there is no CD20 for rituximab to attach to, together with antiretroviral therapy where there is HIV. In the two large United States analyses, HIV status did not affect survival once treatment was given. Drugs used in myeloma, such as bortezomib and lenalidomide, have been added in case series on the basis of the phenotype rather than on randomised evidence. The regimens are in the treatment layer of this family and on the HIV-associated lymphoma page. | NCI PDQ: adult non-Hodgkin lymphoma treatment | 91 |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.